Clinical Trial Design Considerations for the Development of Disease-Modifying Therapies for Type 1 Diabetes

The landscape of type 1 diabetes research is experiencing a pivotal shift as public health organizations, researchers, and pharmaceutical developers pivot toward strategies aimed at altering the fundamental trajectory of the condition rather than merely managing its symptoms. Historically, medical intervention for type 1 diabetes has centered on exogenous insulin replacement therapy—a lifesaving innovation first introduced a century ago, yet one that demands relentless, round-the-clock vigilance from patients and caregivers. Today, a new class of treatments known as disease-modifying therapies, or DMTs, offers the potential to intercept the autoimmune destruction of insulin-producing pancreatic beta cells, thereby preserving the body’s endogenous insulin production.

Despite the promise demonstrated by numerous candidates in early-stage laboratory and clinical evaluations, the translation of these therapies into commercially available treatments has faced systemic bottlenecks. Traditional clinical trial designs for type 1 diabetes have long relied on conventional endpoints that demand extensive timeframes, substantial financial investments, and large participant cohorts. To address these barriers, a landmark publication released in October 2026 in the peer-reviewed journal Diabetes—titled “Clinical Trial Design Considerations for the Development of Disease-Modifying Therapies for Type 1 Diabetes”—outlines a strategic roadmap for modernizing trial frameworks. Authored collaboratively by leading scientific experts and staff from the global advocacy and research organization Breakthrough T1D, the publication sets forth actionable recommendations designed to accelerate the clinical evaluation, regulatory review, and eventual approval of next-generation therapeutic options.

The Biological Imperative of Beta Cell Preservation

To understand the urgency driving this new publication, one must examine the pathophysiology of type 1 diabetes. The condition is characterized by an autoimmune response in which the body’s immune system mistakenly identifies and attacks the insulin-producing beta cells located within the islets of Langerhans in the pancreas. Over time, this progressive destruction leads to a severe deficit or complete absence of endogenous insulin, forcing individuals to rely entirely on external insulin delivery via multiple daily injections or automated pump systems.

Disease-modifying therapies intervene directly in this autoimmune cascade or protect beta cells from cellular stress, effectively halting or slowing the disease’s progression. The clinical rationale is clear: preserving even a fraction of the body’s natural beta cell mass yields profound physiological advantages. Retaining endogenous insulin production is clinically associated with more stable glycemic control, a significantly lower incidence of dangerous acute events such as severe hypoglycemia and diabetic ketoacidosis, and a reduced risk of long-term microvascular and macrovascular complications, including retinopathy, nephropathy, and neuropathy. Furthermore, metabolic management becomes substantially less burdensome when the body retains a baseline capacity to regulate blood glucose independently.

The approval of teplizumab, marketed as Tzield, marked a historic milestone as the first regulatory-approved DMT capable of delaying the onset of clinical stage 3 type 1 diabetes in individuals with stage 2 disease, and its subsequent expansion into recently diagnosed stage 3 populations. While teplizumab validated the concept of immune interception, the type 1 diabetes community requires a diverse arsenal of therapeutic choices. Because patients exhibit wide variability in their genetic backgrounds, immune profiles, and disease trajectories, no single drug will be universally optimal. Providing clinicians and patients with a spectrum of therapies tailored to specific mechanistic targets is essential for personalized medicine in diabetes care.

Historical Bottlenecks in the Drug Development Pipeline

The journey from bench science to clinical availability is notoriously arduous, and DMT development has faced distinct structural hurdles. Although preclinical models and early-phase clinical studies have identified approximately ten distinct disease-modifying therapies capable of preserving or slowing the decline of beta cell function post-diagnosis—verified through biomarkers such as C-peptide levels—very few of these candidates have successfully advanced to pivotal phase 3 clinical trials. Phase 3 trials represent the definitive phase required before submitting applications for regulatory review to agencies such as the U.S. Food and Drug Administration (FDA).

The primary impediment lies in the reliance on legacy clinical trial endpoints. Historically, regulatory frameworks have demanded long-term follow-up periods to measure clinical outcomes such as total daily insulin use, overt sustained hyperglycemia, or the emergence of chronic microvascular complications. These traditional endpoints require years of observation, massive financial outlays, and large patient populations to achieve statistical significance. For a rare or complex autoimmune disease like type 1 diabetes, recruiting and retaining large cohorts for protracted studies creates a severe bottleneck that discourages pharmaceutical investment and delays patient access.

Modernizing the Blueprint: Strategic Solutions for Clinical Trials

The October 2026 publication in Diabetes addresses these systemic inefficiencies by proposing a modernized framework for clinical trial execution. By reimagining how studies are structured, researchers can significantly reduce the duration and cost of development phases while maintaining rigorous standards for safety and efficacy.

A central pillar of this proposed roadmap is the integration of surrogate endpoints—specifically, the measurement of C-peptide. C-peptide is a byproduct created when the pancreas produces proinsulin and splits it into insulin and C-peptide in equimolar amounts. Because exogenous insulin therapies do not contain C-peptide, measuring circulating C-peptide levels provides a direct, objective readout of endogenous beta cell function. Breakthrough T1D and leading endocrinologists have persistently advocated for regulatory agencies to formally accept C-peptide metrics as validated surrogate endpoints. Because changes in C-peptide manifest much earlier in the disease course than long-term glycemic damage or classic complications, utilizing this biomarker allows researchers to assess drug efficacy swiftly, accurately, and with smaller cohorts.

Beyond endpoint modernization, the roadmap highlights four additional strategic considerations for trial design:

1. Matching Mechanisms with Patient Populations: The heterogeneity of type 1 diabetes means that immune-mediated destruction manifests differently across individuals. Future trials must strategically align specific drug mechanisms with distinct patient profiles, taking into account the stage of the disease, genetic predispositions, and underlying immune signatures.
2. Evaluating Combination Therapies: Just as oncology and infectious disease management rely on multi-drug regimens, type 1 diabetes may be most effectively treated by combining therapies with complementary mechanisms of action. By pairing immune-modulating agents with compounds that alleviate cellular stress on beta cells—such as ongoing investigations testing verapamil alongside anti-thymocyte globulin (ATG) in trials like WAVE T1D—researchers aim to achieve synergistic efficacy that surpasses monotherapy.
3. Repurposing Approved Autoimmune Therapeutics: Accelerating the pipeline does not exclusively require entirely novel molecules. Leveraging existing pharmaceutical agents already approved for other autoimmune conditions—such as baricitinib, a JAK inhibitor approved for rheumatoid arthritis and alopecia—allows researchers to bypass redundant foundational safety studies. Investigating these repurposed drugs in phase 3 trials for type 1 diabetes significantly compresses the timeline from initial hypothesis to patient availability.
4. Centering the Lived Experience: Clinical trial architecture must increasingly incorporate patient-reported outcomes and qualitative feedback. Ensuring that the voices and daily realities of individuals living with type 1 diabetes guide trial protocols enhances recruitment, retention, and the ultimate clinical relevance of the resulting therapies.

Broader Implications for the Future of Diabetes Care

The publication of these clinical trial design guidelines arrives at a critical juncture for metabolic research. As the biotechnology and pharmaceutical sectors increasingly recognize the commercial and humanitarian value of disease-modifying interventions, regulatory bodies are under growing pressure to adapt evaluation frameworks to match the speed of scientific innovation.

If adopted widely by regulatory agencies, industry sponsors, and academic institutions, the strategies outlined in the Diabetes manuscript could radically transform the drug development lifecycle. By replacing cumbersome traditional metrics with validated surrogate markers like C-peptide and embracing innovative combination and repurposing paradigms, the clinical research enterprise can streamline the advancement of the numerous promising DMTs currently stalled in early development.

Ultimately, the transition toward immune interception and beta cell preservation represents a paradigm shift away from lifelong disease management toward disease modification and potential prevention. For the millions of individuals worldwide affected by type 1 diabetes, modernizing clinical trial design is not merely an administrative adjustment; it is a vital accelerator designed to deliver safe, effective, and diverse therapeutic options to the clinic as quickly as possible.